Noah Goodman - Apr 8, 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Business Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: Apr 8, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/9/2025, 08:05 AM
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award	$0	+50K	+61394.89%	$0.00	50.1K	Apr 8, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award	$0	+100K		$0.00	100K	Apr 8, 2025	Common Stock	100K	$21.05	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following April 8, 2025, subject to the reporting person's continued employment through each vesting date.
F2	Twenty-five percent (25%) of the shares underlying this stock option shall vest on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.